A pilot pharmacokinetic study of VAL413 in patients with recurrent pediatric solid tumors
Patients aged 2-30 with recurrent pediatric solid tumors including but not limited to neuroblastoma, rhabdomyosarcoma, Ewing sarcoma, hepatoblastoma and medulloblastoma may be eligible for this trial
Business Development Opportunities
Please contact us if you are interested in business opportunities.
;
Careers
Join our team! Visit our website to view available opportunities and apply now.
Investors
All prospective investors, please contact us if you are interested in learning more.